Clinical Trials Logo

Portal Hypertension clinical trials

View clinical trials related to Portal Hypertension.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05765253 Terminated - Vascular Diseases Clinical Trials

Achieving Portal Access With Scorpion Post-Approval Study (APASS)

Start date: July 13, 2023
Phase: N/A
Study type: Interventional

Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure. The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.

NCT ID: NCT03827200 Terminated - Cirrhosis Clinical Trials

A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

Start date: April 11, 2019
Phase: Phase 2
Study type: Interventional

Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin. The purpose of this study is to evaluate the effect of ambrisentan on portal pressure and renal function in patients with advanced liver cirrhosis and with portal hypertension. In this study, portal pressure will be determined at multiple times with the aid of a catheter inserted into the body of the patient. The effect of ambrisentan on the function of the kidney will also be investigated. This study will also evaluate the concentrations of ambrisentan in blood in patients with liver cirrhosis.

NCT ID: NCT03352882 Terminated - Portal Hypertension Clinical Trials

Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness

Start date: August 2016
Phase: N/A
Study type: Interventional

Pilot study examining changes in liver stiffness measured by ultrasound before and after TIPS creation

NCT ID: NCT02929407 Terminated - Portal Hypertension Clinical Trials

A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension

Start date: November 2016
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to investigate safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) after intravenous (IV) administration of FE 204205 in patients with cirrhotic portal hypertension.

NCT ID: NCT01842113 Terminated - Liver Cirrhosis Clinical Trials

Quality of Life and Nutritional Improvements in Cirrhotic Patients

Start date: April 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether taking Rifaximin (Xifaxan) in conjunction with the use of nutritional concepts is effective in improving morbidity and quality of life in cirrhotic patients suffering from hepatic encephalopathy (HE).

NCT ID: NCT01236339 Terminated - Liver Cirrhosis Clinical Trials

Early TIPS for Ascites Study

Start date: December 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate that TIPS with the GORE® VIATORR® TIPS Endoprosthesis improves transplant-free survival compared to LVP alone in patients who have cirrhosis of the liver with portal hypertension and difficult to treat ascites.

NCT ID: NCT00737594 Terminated - Portal Hypertension Clinical Trials

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at two dose levels) as compared to placebo for lowering portal hypertension.

NCT ID: NCT00414869 Terminated - Portal Hypertension Clinical Trials

Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure

Start date: November 2005
Phase: Phase 2
Study type: Interventional

Chronic liver diseases are often characterized by portal hypertension, a major complication involving haemodynamic changes due to increased intrahepatic vascular resistance. It has become well established that nitric oxide (NO) plays a crucial role in the haemodynamic abnormalities that develop in chronic portal hypertension. NCX-1000 is a NO-releasing derivative of ursodeoxycholic acid that would compensate for the defective liver NO production in cirrhosis. This study intends to demonstrate the desired therapeutic activity (reduction in portal pressure) in a small number of target patients, to assess the safety and tolerability after repeated oral administrations of NCX-1000, and to get preliminary pharmacokinetic data in this population.